EmailThe Healthcare sector -1.92% is trading in line with the overall market -1.8%
News: DARA -3.3% announces positive results from a successfully completed Phase 1b clinical study of DB959 for the treatment of type 2 diabete, UTMD +1.8% approved quarterly cash dividend of $0.24 per share of common stock, prior $0.235 per share, MD +1.4% announced the acquisition of pediatric surgery practice, which was acquired for cash and the transaction is %expected to be immediately accretive, DGX -1.59% announces launch of Simplexa Direct Test for influenza and respiratory viruses in Europe, PRGO -1.2% announces launch of generic version of Elestat, SNTS -2.6% presents pooled data from Budesonide MMX Phase III clinical studies; receives conditional FDA acceptance of trade name and EXEL -40% announces the co did not reach a timely agreement under a special protocol assessment (SPA) with the FDA on the proposed design and analysis of the '306 trial.
Broker Research: PFE +2.1% downgraded at Standpoint, ANTH +2.3% initiated with a Buy at Deutsche Bank, AGP -0.1% upgraded at BofA/Merrill, NUVA -2.7% downgraded at Rodman and Renshaw, ARUN 1.6% initiated with a Hold at Deutsche Bank, VOLC -4.6% downgraded at JMP Securities, TRNX -7.1% downgraded at JP Morgan, and EXEL -38% downgraded at Piper Jaffray.
